CBV regimen
|
WikiDoc Resources for CBV regimen |
|
Articles |
|---|
|
Most recent articles on CBV regimen Most cited articles on CBV regimen |
|
Media |
|
Powerpoint slides on CBV regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CBV regimen at Clinical Trials.gov Clinical Trials on CBV regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CBV regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CBV regimen Discussion groups on CBV regimen Patient Handouts on CBV regimen Directions to Hospitals Treating CBV regimen Risk calculators and risk factors for CBV regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CBV regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BCNU/CTX/VP-16; Carmustine/Cyclophosphamide/Etoposide; CBV
Overview
CBV regimen refers to cyclophosphamide (Cytoxan), carmustine (BCNU), and etoposide (VP-16), three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapy.[1]
Regimen
CCyclophosphamide
BCarmustine (BCNU)
VEtoposide (VP-160)
Indications
References
- ↑ Skeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."
- ↑ Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N; et al. (1987). "High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia". Cancer. 59 (6): 1083–6. PMID 3545428.